Practical consideration for successful sequential tumor biopsies in first-in-human trials
-
Published:2022-04-11
Issue:4
Volume:40
Page:841-849
-
ISSN:0167-6997
-
Container-title:Investigational New Drugs
-
language:en
-
Short-container-title:Invest New Drugs
Author:
Koyama Takafumi, Shimizu Toshio, Sato Jun, Katsuya Yuki, Iwasa Satoru, Kondo Shunsuke, Yoshida Tatsuya, Sudo Kazuki, Nishino Makoto, Takiguchi Yuichi, Yonemori Kan, Yamamoto NoboruORCID
Abstract
AbstractIn first-in-human (FIH) trials, sequential tumor biopsies, i.e., two consecutive tumor biopsies, the first performed at baseline (pretreatment) and the second during the early treatment period (on-treatment), provide proof of concept in investigational new drugs. We evaluated the success of sequential tumor biopsies in FIH trials, and explored approaches for improved success rates. We retrospectively reviewed the sequential tumor biopsies required in 17 of 52 FIH trials conducted from 2015 to 2020. One hundred and thirty-eight patients were identified. Success of either pretreatment or on-treatment biopsy alone, and of sequential tumor biopsies, was defined as the acquisition of viable tumor cells and as obtaining tumor cells from both biopsy specimens, respectively. The success rates of pretreatment and on-treatment biopsy were 98.6% and 94.2%, respectively, and of sequential tumor biopsies was 70.3%. Adverse events associated with the pretreatment biopsies (33.3% positive; 72.0% negative) and timing of the first imaging assessment (before on-treatment biopsy = 40.0%; after on-treatment biopsy = 82.7%) correlated with successful sequential tumor biopsies. The reasons for unsuccessful sequential tumor biopsies could be categorized into two groups: 1) patient refusal of the on-treatment biopsy (most frequently due to early disease progression); and 2) absence of tumor cells in the pretreatment or on-treatment biopsy specimen. We propose an approach to achieving greater success in sequential tumor biopsies in FIH trials; the first imaging assessment during the study should be scheduled after on-treatment biopsy. (Registration number UMIN000042487, Date of registration November 18, 2020).
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology,Oncology
Reference22 articles.
1. Kummar S, Do K, Coyne GO, Chen A, Ji J, Rubinstein L, Doroshow JH (2016) Establishing proof of mechanism: Assessing target modulation in early-phase clinical trials. Semin Oncol 43(4):446–452. https://doi.org/10.1053/j.seminoncol.2016.06.002 2. Lim C, Tsao MS, Le LW, Shepherd FA, Feld R, Burkes RL, Liu G, Kamel-Reid S, Hwang D, Tanguay J, da Cunha SG, Leighl NB (2015) Biomarker testing and time to treatment decision in patients with advanced nonsmall-cell lung cancer. Ann Oncol 26(7):1415–1421. https://doi.org/10.1093/annonc/mdv208 3. Gastman B, Agarwal PK, Berger A, Boland G, Broderick S, Butterfield LH, Byrd D, Fecci PE, Ferris RL, Fong Y, Goff SL, Grabowski MM, Ito F, Lim M, Lotze MT, Mahdi H, Malafa M, Morris CD, Murthy P, Neves RI, Odunsi A, Pai SI, Prabhakaran S, Rosenberg SA, Saoud R, Sethuraman J, Skitzki J, Slingluff CL, Sondak VK, Sunwoo JB, Turcotte S, Yeung CC, Kaufman HL (2020) Defining best practices for tissue procurement in immuno-oncology clinical trials: consensus statement from the Society for Immunotherapy of Cancer Surgery Committee. J Immunother Cancer 8 (2). https://doi.org/10.1136/jitc-2020-001583 4. Parseghian CM, Tam AL, Yao J, Ensor J Jr, Ellis LM, Raghav K, Overman MJ (2019) Assessment of Reported Trial Characteristics, Rate of Publication, and Inclusion of Mandatory Biopsies of Research Biopsies in Clinical Trials in Oncology. JAMA Oncol 5(3):402–405. https://doi.org/10.1001/jamaoncol.2018.4640 5. Kimmelman J, Resnik DB, Peppercorn J, Ratain MJ (2017) Burdensome Research Procedures in Trials: Why Less Is More. J Natl Cancer Inst 109 (4). https://doi.org/10.1093/jnci/djw315
|
|